Policy
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
Wolters Kluwer, Health now equips astronauts at the National Aeronautics and Space Administration on board the International Space Station with the most current medical information and access to expert-authored recommendations.
labfolder is the first company amongst electronic laboratory notebook (ELN) and laboratory information management (LIMS) software vendors to announce its highly-ranked Net Promoter Score® (NPS®).
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
The FY19 Defense Appropriations Act provides $15 million to the Department of Defense Neurofibromatosis Research Program to support innovative, high-impact NF research.
Department of Defense Parkinson’s Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $16 million to the Department of Defense Parkinson’ Research Program to support research to understand, prevent, diagnose, and treat Parkinson’s disease.
The life sciences industry is incredibly important to the financial ecosystem of the Golden State. Last year the industry generated total annual revenue of $177.1 billion in the state.
Allergan, which has been a leader in the migraine space, hopes to have a new treatment available for patients using a new mechanism of action for acute treatment of migraine.
Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests